Zurcher Kantonalbank Zurich Cantonalbank lessened its position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) by 4.3% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 37,809 shares of the biotechnology company’s stock after selling 1,696 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in BioMarin Pharmaceutical were worth $3,371,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in BMRN. American Century Companies Inc. increased its holdings in shares of BioMarin Pharmaceutical by 64.5% in the 3rd quarter. American Century Companies Inc. now owns 614,862 shares of the biotechnology company’s stock worth $57,225,000 after acquiring an additional 241,183 shares during the period. TCW Group Inc. increased its holdings in shares of BioMarin Pharmaceutical by 20.1% in the 3rd quarter. TCW Group Inc. now owns 1,072,969 shares of the biotechnology company’s stock worth $99,862,000 after acquiring an additional 179,879 shares during the period. Pictet Asset Management Ltd. increased its holdings in shares of BioMarin Pharmaceutical by 17.0% in the 3rd quarter. Pictet Asset Management Ltd. now owns 1,134,622 shares of the biotechnology company’s stock worth $105,599,000 after acquiring an additional 164,788 shares during the period. Westfield Capital Management Co. LP increased its holdings in shares of BioMarin Pharmaceutical by 136.5% in the 3rd quarter. Westfield Capital Management Co. LP now owns 263,925 shares of the biotechnology company’s stock worth $24,563,000 after acquiring an additional 152,315 shares during the period. Finally, First Trust Advisors LP increased its holdings in shares of BioMarin Pharmaceutical by 33.6% in the 3rd quarter. First Trust Advisors LP now owns 574,938 shares of the biotechnology company’s stock worth $53,509,000 after acquiring an additional 144,651 shares during the period. 98.83% of the stock is currently owned by institutional investors and hedge funds.

A number of analysts recently weighed in on BMRN shares. Stifel Nicolaus dropped their price objective on shares of BioMarin Pharmaceutical from $107.00 to $105.00 and set a “buy” rating on the stock in a report on Friday, October 27th. BidaskClub cut shares of BioMarin Pharmaceutical from a “sell” rating to a “strong sell” rating in a report on Saturday, January 20th. BMO Capital Markets reaffirmed a “buy” rating and issued a $117.00 price objective on shares of BioMarin Pharmaceutical in a report on Friday, October 20th. JPMorgan Chase & Co. set a $130.00 price objective on shares of BioMarin Pharmaceutical and gave the stock a “buy” rating in a report on Sunday, October 29th. Finally, Credit Suisse Group reissued an “outperform” rating and set a $124.00 target price (up previously from $114.00) on shares of BioMarin Pharmaceutical in a research note on Thursday, October 19th. Two equities research analysts have rated the stock with a sell rating, eight have issued a hold rating, fifteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $111.60.

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) opened at $80.33 on Friday. The stock has a market cap of $14,429.05, a P/E ratio of -89.26 and a beta of 1.71. The company has a quick ratio of 3.81, a current ratio of 4.91 and a debt-to-equity ratio of 0.41. BioMarin Pharmaceutical Inc. has a 52 week low of $78.50 and a 52 week high of $100.51.

In other news, CEO Jean Jacques Bienaime sold 20,000 shares of BioMarin Pharmaceutical stock in a transaction that occurred on Friday, December 29th. The shares were sold at an average price of $89.75, for a total value of $1,795,000.00. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Elaine J. Heron sold 800 shares of BioMarin Pharmaceutical stock in a transaction that occurred on Thursday, December 14th. The stock was sold at an average price of $88.90, for a total transaction of $71,120.00. Following the completion of the transaction, the director now directly owns 38,385 shares in the company, valued at approximately $3,412,426.50. The disclosure for this sale can be found here. Insiders sold a total of 90,750 shares of company stock worth $8,159,588 in the last ninety days. Corporate insiders own 1.85% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Zurcher Kantonalbank Zurich Cantonalbank Has $3.37 Million Position in BioMarin Pharmaceutical Inc. (BMRN)” was originally reported by Daily Political and is the sole property of of Daily Political. If you are accessing this article on another site, it was illegally stolen and republished in violation of United States and international copyright & trademark law. The legal version of this article can be read at https://www.dailypolitical.com/2018/02/10/zurcher-kantonalbank-zurich-cantonalbank-has-3-37-million-position-in-biomarin-pharmaceutical-inc-bmrn.html.

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc is a biotechnology company. The Company develops and commercializes pharmaceuticals for various diseases and medical conditions. As of December 31, 2016, the Company’s therapy portfolio consisted of five products, and multiple clinical and pre-clinical product candidates. Its commercial products include Aldurazyme (laronidase) for Mucopolysaccharidosis I (MPS I), Firdapse (amifampridine phosphate) for Lambert Eaton Myasthenic Syndrome (LEMS), Kuvan (sapropterin dihydrochloride) for phenylketonuria (PKU), Naglazyme (galsulfase) for Mucopolysaccharidosis VI (MPS VI) and Vimizim (elosulfase alpha) for Mucopolysaccharidosis IV Type A (MPS IV A).

Want to see what other hedge funds are holding BMRN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BioMarin Pharmaceutical Inc. (NASDAQ:BMRN).

Institutional Ownership by Quarter for BioMarin Pharmaceutical (NASDAQ:BMRN)

Receive News & Ratings for BioMarin Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.